<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01570738</url>
  </required_header>
  <id_info>
    <org_study_id>Carmel-001</org_study_id>
    <nct_id>NCT01570738</nct_id>
  </id_info>
  <brief_title>Validation of Home Sleep Testing (WP) Compared to an Overnight Sleep Testing in the Sleep Laboratory</brief_title>
  <official_title>Validation of Home Sleep Testing (WP) Compared to an Overnight Sleep Testing in the Sleep Laboratory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Itamar-Medical, Israel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Itamar-Medical, Israel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea syndrome (OSAS) is considered to be a major public health problem.&#xD;
      The prevalence of OSAS is estimated at 2% and 4% for adult women and men respectively, most&#xD;
      of whom are undiagnosed and untreated. The prevalence of snoring in children is high - 5% in&#xD;
      the age group of 6 and less and about 1.5% above. The in-lab sleep study using full&#xD;
      Polysomnography (PSG) and the manual scoring criteria set by the American Academy of Sleep&#xD;
      Medicine was considered the gold standard for OSAS diagnosis. The high cost of in-lab full&#xD;
      night PSG, together with long waiting lists for sleep studies, have led to the commonly used&#xD;
      procedure of &quot;split-night&quot; for OSAS patients, as well as to the development of a variety of&#xD;
      ambulatory sleep study systems. The primary study objective is to compare the efficacy of the&#xD;
      WatchPAT (WP), as an ambulatory device for aiding in the diagnosis of sleep disorders for&#xD;
      subjects from age 5 to 90, to the manual scoring of the PSG that serves as a &quot;gold standard&quot;.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compare sleep data collected from the Watch-PAT device to PSG data</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Sleep Disorders</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults and children with and without sleep disorders, referred to Carmel Medical Center&#xD;
        clinical sleep laboratory for an overnight sleep study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 5-90&#xD;
&#xD;
          2. Subjects that are able to read understand and sign the informed consent form to&#xD;
             undergo an overnight sleep study in the clinical sleep laboratory&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Permanent pacemaker.&#xD;
&#xD;
          2. Severe lung disease.&#xD;
&#xD;
          3. Peripheral neuropathy.&#xD;
&#xD;
          4. Finger deformity that precludes adequate sensor appliance.&#xD;
&#xD;
          5. Using one of the following medications: short/Long acting nitrates (less than 3 hours&#xD;
             before the sleep study) or alpha-adrenergic receptor blockers (less than 24 hours&#xD;
             before the sleep study).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giora Pillar</last_name>
      <email>giorapi@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Giora Pillar, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 28, 2012</study_first_submitted>
  <study_first_submitted_qc>April 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep disorders</keyword>
  <keyword>sleep apnea</keyword>
  <keyword>ambulatory device</keyword>
  <keyword>polysomnography</keyword>
  <keyword>WatchPAT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

